Precision BioSciences (NASDAQ:DTIL) Stock Lifted to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Precision BioSciences (NASDAQ:DTIL) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Several other equities research analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Tuesday. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.25.

Precision BioSciences Price Performance

DTIL stock opened at $10.60 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 12.82 and a current ratio of 10.47. The business has a 50-day simple moving average of $6.90 and a two-hundred day simple moving average of $6.62. The company has a market capitalization of $296.16 million, a P/E ratio of -8.55 and a beta of 1.34. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $11.29.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.57. Precision BioSciences had a negative return on equity of 56.69% and a negative net margin of 96.73%. The firm had revenue of $1.25 million during the quarter, compared to the consensus estimate of $1.38 million. Research analysts expect that Precision BioSciences will post -2.60 EPS for the current fiscal year.

Institutional Investors Weigh In On Precision BioSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in DTIL. Russell Investments Group Ltd. boosted its stake in shares of Precision BioSciences by 4,217.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 82,818 shares of the company’s stock worth $518,000 after buying an additional 80,900 shares during the last quarter. Engineers Gate Manager LP bought a new position in shares of Precision BioSciences in the second quarter valued at approximately $164,000. Squarepoint Ops LLC increased its position in shares of Precision BioSciences by 212.7% during the second quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after acquiring an additional 93,258 shares during the last quarter. Corient Private Wealth LP increased its position in shares of Precision BioSciences by 70.4% during the second quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock valued at $1,926,000 after acquiring an additional 101,206 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Precision BioSciences during the second quarter worth $467,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Key Headlines Impacting Precision BioSciences

Here are the key news stories impacting Precision BioSciences this week:

• Positive Sentiment: HC Wainwright sharply reduced its projected FY2026 loss to $2.01 per share from $3.47, and its Q4 2026 loss estimate to $0.72 from $1.20. This is a more favorable near-term earnings outlook.
• Positive Sentiment: Wall Street Zen upgraded DTIL to Hold, a modestly more favorable rating change. Article: Precision BioSciences upgraded to Hold at Wall Street Zen
• Negative Sentiment: HC Wainwright lowered its estimates for each quarter of 2027 and for FY2027–FY2029, implying larger expected losses in several periods. It also trimmed its FY2030 earnings forecast to $1.13 per share from $1.24. These longer-term reductions temper the improved 2026 outlook.

About Precision BioSciences

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.